Abecma Market Report 2026

Abecma Market Overview

• The Abecma market growth in the historic period has been driven by breakthrough CAR T clinical outcomes, rising multiple myeloma incidence • Market expansion is supported by expansion into earlier treatment lines, improvements in manufacturing efficiency • Growth Driver: Rising Multiple Myeloma Cases Fuel Growth In The Abecma Market • Market Trend: Innovations In CAR T Cell Therapy Advancements In Abecma For Multiple Myeloma Treatment • North America was the largest region in 2025.

What Is Covered Under Abecma Market?

Abecma (idecabtagene vicleucel) is a CAR T-cell therapy used to treat relapsed or refractory multiple myeloma by targeting and eliminating malignant plasma cells. It involves reprogramming a patient's own immune cells (T cells) to target and kill cancer cells. The main indications of abecma are multiple myeloma, b-cell lymphoma (bcl), and acute lymphoblastic leukemia (all). Multiple myeloma is a type of blood cancer that originates in the plasma cells, which are a type of white blood cell found in the bone marrow. These are used by various end users such as adults, and geriatric and are by various distribution channels such as hospitals and clinics, retail and specialty pharmacies, and online pharmacies.

What Is The Abecma Market Growth Forecast?

The growth in the forecast period can be attributed to expansion into earlier treatment lines, improvements in manufacturing efficiency, increasing oncology investment, growing patient eligibility, development of next generation CAR T therapies. Major trends in the forecast period include rising adoption of CAR T cell therapies, expansion of advanced cell based oncology, growth of personalized cancer treatments, increasing use in refractory multiple myeloma, advancements in autologous cell processing.

What Is The Driver Of The Abecma Market?

The rise in the prevalence of multiple myeloma is expected to propel the growth of the abecma market going forward. Multiple myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell found in bone marrow. The rising prevalence of multiple myeloma is due to aging population, improved diagnostic techniques, and increasing awareness of the disease. Abecma, a CAR T-cell therapy, is helpful in treating multiple myeloma by utilizing genetically modified immune cells to target and destroy cancerous plasma cells, offering a novel option for patients with relapsed or refractory forms of the disease. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, in 2024 there were projected to be 35,780 cases of myeloma compared to 34,470 in 2022. Therefore, the rise in the prevalence of multiple myeloma drives the abecma industry.

Key Players In The Global Abecma Market

Major companies operating in the abecma market are Bristol-Myers Squibb

Global Abecma Market Trends and Insights

Major companies operating in the abecma market are focusing on developing innovative treatments such as chimeric antigen receptor T cell therapy (CAR T) to enhance patient outcomes, target specific cancer types more effectively, and expand the therapeutic options available for individuals with relapsed or refractory multiple myeloma. Chimeric antigen receptor T cell therapy (CAR T) is an advanced form of immunotherapy used primarily to treat certain types of cancers, such as leukemia and lymphoma. It involves genetically engineering a patient’s own T cells (a type of white blood cell) to better recognize and destroy cancer cells. For instance, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, received the approval of the European Commission (EC) for Abecma (idecabtagene vicleucel; ide-cel), a CAR T-cell therapy designed to treat adult patients with relapsed and refractory multiple myeloma. This approval specifically targets patients who have undergone at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, and who have shown disease progression following their last treatment.

What Are Latest Mergers And Acquisitions In The Abecma Market?

In January 2024, 2Seventy Bio Inc., a US-based biotechnology company, partnered with Bristol Myers Squibb. With this partnership, 2Seventy Bio aims to enhance the growth trajectory of Abecma, with plans for expanding treatment access and educating healthcare providers about its benefits. The company is preparing for a potential regulatory approval that would broaden Abecma's indication in the treatment landscape. Bristol Myers Squibb, is a US-based pharmaceutical company engaged in development of Abecma drug.

What Defines the Abecma Market?

The abecma market consists of sales of CAR T-cell therapies, personalized treatments, and immuno-oncology solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Abecma Market Report 2026?

The abecma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the abecma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.